Several anti-angiogenic therapies directed at these molecules have been approved by the Food and Drug Administration for treating cancer, such as the humanized antibody Avastin (bevacizumab), which targets VEGF-A, and the tyrosine kinase inhibitor sorafenib, which targets Raf and VEGF and PDGF receptors [38, 39]. Here, VEGFA is linked to cancer.